Affinity Asset Advisors, LLC
- SEC CIK
- 0001773195
- Latest filing
- Aug 13, 2026
Holdings in Q4 2022
Holdings as of Dec 31, 2022, filed Feb 13, 2023. Long positions only; changes compare share counts with Q3 2022.
- Positions
- 54
- +7 vs. Q3 2022
- Portfolio value
- $218.2M
- +$1.25M (+0.6%) vs. Q3 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| KDNYChinook Therapeutics, Inc. | COM | 818,035 | $21.4M | 9.8% | +4,037+0.5% | Added | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 70,000 | $20.3M | 9.3% | −30,000−30.0% | Reduced | History |
| ESTAEstablishment Labs Holdings Inc. | COM | 190,767 | $12.5M | 5.7% | −135,901−41.6% | Reduced | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 70,997 | $8.67M | 4.0% | −29,003−29.0% | Reduced | History |
| BMRNBiomarin Pharmaceutical Inc | COM | 80,000 | $8.28M | 3.8% | +80,000 | New | History |
| RXDXPrometheus Biosciences, Inc. | COM | 75,000 | $8.25M | 3.8% | +50,000+200.0% | Added | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 312,498 | $8.17M | 3.7% | −37,502−10.7% | Reduced | History |
| VTYXVentyx Biosciences, Inc. | COM | 240,623 | $7.89M | 3.6% | +70,623+41.5% | Added | History |
| MORFMorphic Holding, Inc. | COM | 280,921 | $7.51M | 3.4% | +134,430+91.8% | Added | History |
| ACLXArcellx, Inc. | COMMON STOCK | 240,143 | $7.44M | 3.4% | +30,005+14.3% | Added | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 1,143,531 | $7.17M | 3.3% | −146,980−11.4% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 472,482 | $7.04M | 3.2% | +72,439+18.1% | Added | History |
| CERECerevel Therapeutics Holdings, Inc. | COM | 215,000 | $6.78M | 3.1% | +215,000 | New | History |
| NARIInari Medical, Inc. | Stock | 90,000 | $5.72M | 2.6% | −30,000−25.0% | Reduced | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 45,000 | $5.12M | 2.3% | +45,000 | New | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 258,115 | $5.05M | 2.3% | −9,679−3.6% | Reduced | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 110,000 | $4.90M | 2.2% | +30,000+37.5% | Added | History |
| Bellus Health Inc New07987C204 | COM NEW | 573,678 | $4.72M | 2.2% | +100,081+21.1% | Added | – |
| AZNAstraZeneca PLC | SPONSORED ADR | 60,000 | $4.07M | 1.9% | −90,000−60.0% | Reduced | History |
| CYTKCytokinetics Inc | COM NEW | 87,601 | $4.01M | 1.8% | +22,601+34.8% | Added | History |
| BridgeBio Pharma, Inc.10806XAD4 | NOTE 2.250% 2/0 | – | $3.90M | 1.8% | – | – | – |
| BridgeBio Pharma, Inc.10806XAB8 | NOTE 2.500% 3/1 | – | $3.41M | 1.6% | – | – | – |
| KURAKura Oncology, Inc. | COM | 268,747 | $3.34M | 1.5% | −407,006−60.2% | Reduced | History |
| VKTXViking Therapeutics, Inc. | COM | 350,000 | $3.29M | 1.5% | +100,000+40.0% | Added | History |
| LNTHLantheus Holdings, Inc. | Stock | 60,630 | $3.09M | 1.4% | −69,370−53.4% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 60,000 | $2.88M | 1.3% | +60,000 | New | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 100,000 | $2.54M | 1.2% | +100,000 | New | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 375,000 | $2.40M | 1.1% | +375,000 | New | History |
| KPTIKaryopharm Therapeutics Inc. | COM | 661,264 | $2.25M | 1.0% | +661,264 | New | History |
| COGTCogent Biosciences, Inc. | COM | 193,064 | $2.23M | 1.0% | +38,977+25.3% | Added | History |
| PNTPOINT Biopharma Global Inc. | COM | 303,218 | $2.21M | 1.0% | −443,358−59.4% | Reduced | History |
| XENEXenon Pharmaceuticals Inc. | COM | 50,000 | $1.97M | 0.9% | +50,000 | New | History |
| ARGXArgenx SE | SPONSORED ADR | 5,000 | $1.89M | 0.9% | +5,000 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 247,891 | $1.82M | 0.8% | +137,891+125.4% | Added | History |
| VINCVincerx Pharma, Inc. | COM NEW | 1,492,771 | $1.52M | 0.7% | 00.0% | Unchanged | History |
| Intrexon Corp46122TAA0 | NOTE 3.500% 7/0 | – | $1.49M | 0.7% | – | – | – |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 460,328 | $1.43M | 0.7% | +217,811+89.8% | Added | History |
| Esperion Therapeutics Inc Ne29664WAB1 | NOTE 4.000%11/1 | – | $1.36M | 0.6% | – | New | – |
| KALVKalVista Pharmaceuticals, Inc. | COM | 188,292 | $1.27M | 0.6% | +91,974+95.5% | Added | History |
| BCABBioAtla, Inc. | COM | 150,000 | $1.24M | 0.6% | +150,000 | New | History |
| DYNDyne Therapeutics, Inc. | COM | 92,170 | $1.07M | 0.5% | +92,170 | New | History |
| LIANYLianBio | SPONSORED ADS | 650,000 | $1.07M | 0.5% | +100,000+18.2% | Added | History |
| NRIXNurix Therapeutics, Inc. | COM | 80,000 | $878.4K | 0.4% | +80,000 | New | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 40,000 | $780.0K | 0.4% | +40,000 | New | History |
| FHTXFoghorn Therapeutics Inc. | COM | 109,991 | $701.7K | 0.3% | +109,991 | New | History |
| SGENSeagen Inc. | COM | 5,000 | $642.5K | 0.3% | +5,000 | New | History |
| CNTXContext Therapeutics Inc. | COM | 883,654 | $583.7K | 0.3% | 00.0% | Unchanged | History |
| INZYInozyme Pharma, Inc. | COM | 500,000 | $525.0K | 0.2% | +500,000 | New | History |
| NUVBNuvation Bio Inc. | COM CL A | 250,000 | $480.0K | 0.2% | +250,000 | New | History |
| Immatics N.V.N44445117 | *W EXP 07/01/202 | 187,204 | $469.9K | 0.2% | 00.0% | Unchanged | – |
| MISTMilestone Pharmaceuticals Inc. | COM | 100,000 | $396.0K | 0.2% | +100,000 | New | History |
| SCLXWScilex Holding Co | *W EXP 11/10/202 | 18,099 | $3.42K | <0.1% | +18,099 | New | History |
| Medicus Sciences AcquisitionG5960S124 | *W EXP 02/12/202 | 33,333 | $2.93K | <0.1% | 00.0% | Unchanged | – |
| SCLXScilex Holding Co | COM | 463 | $1.85K | <0.1% | +463 | New | History |
Options (8)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| BMYBristol Myers Squibb Co | Stock | $12.6M | – |
| MRNAModerna, Inc. | Stock | $5.39M | – |
| AMGNAmgen Inc | Stock | $5.25M | – |
| GERNGeron Corp | COM | $2.56M | $2.03M |
| VRNAVerona Pharma plc | SPONSORED ADS | – | $2.74M |
| VKTXViking Therapeutics, Inc. | COM | – | $2.35M |
| NVAXNovavax Inc | COM NEW | $2.06M | – |
| NVCRNovoCure Ltd | ORD SHS | – | $1.83M |
Sold out since Q3 2022 (14)
Positions held at the end of Q3 2022 that are gone from this filing.
| Security | Class | Shares in Q3 2022 | Value in Q3 2022 | % of portfolio in Q3 2022 | History |
|---|---|---|---|---|---|
| GBTGlobal Blood Therapeutics, Inc. | COM | 190,000 | $12.9M | 6.0% | History |
| SNYSanofi | SPONSORED ADR | 300,000 | $11.4M | 5.3% | History |
| Retrophin Inc761299AB2 | NOTE 2.500% 9/1 | – | $11.1M | 5.1% | – |
| Nanostring Technologies Inc63009RAD1 | NOTE 2.625% 5/0 | – | $8.54M | 3.9% | – |
| SWTXSpringWorks Therapeutics, Inc. | COM | 175,000 | $4.99M | 2.3% | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 170,000 | $3.68M | 1.7% | History |
| ARYEARYA Sciences Acquisition Corp V | CLASS A ORD SHS | 352,500 | $3.46M | 1.6% | History |
| GSKGSK plc | ADR | 75,000 | $2.21M | 1.0% | History |
| ACRSAclaris Therapeutics, Inc. | COM | 136,434 | $2.15M | 1.0% | History |
| NAUTNautilus Biotechnology, Inc. | COM | 372,476 | $790.0K | 0.4% | History |
| RCORRenovacor, Inc. | COM | 199,490 | $503.0K | 0.2% | History |
| TNGXTango Therapeutics, Inc. | COM | 81,982 | $297.0K | 0.1% | History |
| Vickers Vantage Corp IG9440B115 | *W EXP 09/15/202 | 100,000 | $17.0K | <0.1% | – |
| Renovacor, Inc.75989E114 | *W EXP 99/99/999 | 75,000 | $6.00K | <0.1% | – |